Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

• US 6,908,902 B2
• Filed: 01/24/2002
• Issued: 06/21/2005
• Est. Priority Date: 02/02/2001
• Status: Expired due to Term

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Inventors: Plata-Salaman, Carlos, Smith-Swintosky, Virginia
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): McIntosh, III, Traviss C.
• Application Number:
  US10/056,828
• Publication Number:
  US 20020169109A1
• Time in Patent Office: 1,244 Days
• Field of Search: 514/23, 514/451, 424/9.34
• US Class Current: 514/23
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin.

Claims

1. A method for promoting neurite outgrowth in a subject, comprising administering an amount of topiramate and erythropoietin effective to promote the neurite outgrowth;

wherein the amount of topiramate and the amount of erythropoietin are selected to produce a synergistic effect.

2. The method of claim 1, wherein the amount of topiramate is from about 10 to 1000 mg.

3. The method of claim 1, wherein the erythropoietin is epoetin alfa.

4. The method of claim 1, wherein the amount of erythropoietin is from about 1 to 15000 I.U./kg.

5. The method of claim 1, wherein said subject has epilepsy.

6. A pharmaceutical composition comprising topiramate, erythropoietin and a pharmaceutically acceptable carrier.

7. A process for making a pharmaceutical composition comprising mixing topiramate, erythropoietin and a pharmaceutically acceptable carrier.